Communiqués AroCell AB

Actions

Marché Fermé - Nasdaq Stockholm Autres places de cotation 17:29:59 05/06/2024			Varia. 5j.	Varia. 1 janv.
0,436 ^SEK	+2,83%		+8,46%	-0,23%

03/05	AroCell AB (publ) annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
22/02	AroCell AB (publ) annonce ses résultats pour le quatrième trimestre clos le 31 décembre 2023	CI

AroCell AB (publ) Interim Report January 1st to March 31st, 2024	06/05	AQ
AroCell Q1 - Unrecognized and going well	06/05	AQ
AroCell AB (publ) Interim Report January 1st to March 31st, 2024	03/05	AQ
AroCell - New patent approved on the US market	19/04	AQ
New patent approved on the US market	18/04	AQ
AroCell Attends Three Prestigious Events: AACR, EAU Congress and COG Nordics	16/04	PU
AroCell publishes the Annual Report for 2023	15/04	AQ
AroCell publishes the Annual Report for 2023	12/04	AQ
The nomination committee's proposal for the board of AroCell for the Annual General Meeting 2024	12/03	AQ
New Study: UBC Rapid can reduce the number of cystoscopies necessary in bladder cancer patients, enabling cost-effective follow-up	12/03	AQ
Two Accepted Abstracts at AACR 2024 Explore Clinical Applications of TK1 Biomarker	11/03	AQ
AroCell : Presentation at LabRoots 2024	04/03	PU
AroCell Q4 - Nearing positive operating cash flow	23/02	AQ
AroCell AB (publ) Interim Report January 1st to December 31st, 2023	22/02	AQ
Ellen Dittberner, AroCell's CFO, will be taking parental leave, and Lars Jakobsson will step in as the interim CFO.	01/02	AQ
AroCell has obtained regulatory approval for TUBEX TF in Ethiopia	26/01	AQ
AroCell has obtained regulatory approval for TUBEX® TF in Ethiopia	25/01	AQ
AroCell - Serum TK1 protein levels can predict survival of prostate cancer patients	16/01	AQ
Serum TK1 protein levels can predict survival of prostate cancer patients	15/01	AQ
AroCell nomination committee for the AGM 2024	16/11	AQ

Aucun résultat pour cette recherche